FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Odence-Ford Marion (Last) (First) (Middle) C/O OPTIMIZERX CORPORATION 400 WATER STREET, SUITE 200 (Street) ROCHESTER MI 48307				3. I	2. Issuer Name and Ticker or Trading Symbol OptimizeRx Corp [OPRX] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)					6. I Lin	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				
(City)	(St	ate) ((Zip)		Person										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			Fransaction te onth/Day/Ye	Execution Date,		Code (Ins	on Dispos str. 5)	rities Acquir ed Of (D) (Ins	str. 3, 4 and	Benefici	es I ally (Following (d tion(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) if any (Code (I of ative (Month/Day/Year) 8)		insaction of E			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title at Amount Securitie Underlyin Derivativ (Instr. 3 a		f g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$43.24	03/01/2022		A		4,690		(1)	03/01/2027	Common Stock	4,690	\$0	4,690	D	
Restricted Stock Units	(2)	03/01/2022		A		2,313		(3)	(3)	Common Stock	2,313	\$0	2,313	D	

Explanation of Responses:

- $1. \ The stock option vests in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date.\\$
- 2. Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.
- 3. The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.

> 03/03/2022 /s/ Marion Odence-Ford

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.